Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Matthew Maurer"'
Autor:
Angie Mae Rodday, Susan K. Parsons, Jenica N. Upshaw, Jonathan W. Friedberg, Andrea Gallamini, Eliza Hawkes, David Hodgson, Peter Johnson, Brian K. Link, Eric Mou, Kerry J. Savage, Pier Luigi Zinzani, Matthew Maurer, Andrew M. Evens
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
PURPOSE The International Prognostic Score (IPS) has been used in classic Hodgkin lymphoma (cHL) for 25 years. However, analyses have documented suboptimal performance of the IPS among contemporarily treated patients. Harnessing multisource individua
Autor:
Katherine D. Crew, Maika Onishi, Matthew Maurer, Kevin Kalinsky, Donna Buono, Elizabeth Shane, Dawn L. Hershman, Madeleine B Hopson, Danielle Awad
Publikováno v:
Clinical Breast Cancer. 20:e327-e333
Ovarian suppression from chemotherapy results in bone loss in premenopausal women with breast cancer (BC). Less is known about bone microarchitecture changes. We used high-resolution peripheral quantitative computed tomography (HR-pQCT) to measure vo
Autor:
Erin Honan, Melissa K. Accordino, Ruby Wu, Kathleen Fenn, Tizita Z. Zeleke, Kevin Kalinsky, Cody Chiuzan, Qingfei Pan, Dawn L. Hershman, Jose Silva, Jiyang Yu, Matthew Maurer, Meghna S. Trivedi, Katherin D Crew, Maika Onishi, Sean A. Kelly
Publikováno v:
Cancer Research. 80:P1-19
Background:HDAC6, a cytoplasmic histone deacetylase, impacts cell viability by influencing protein metabolism, microtubule dynamics, and chaperone function. ACY-1215 is an orally active, selective HDAC6 inhibitor. Preclinical studies have demonstrate
Autor:
Shing M. Lee, Dawn L. Hershman, Melissa K. Accordino, Katherine D. Crew, Kathleen Fenn, Kevin Kalinsky, Meghna S. Trivedi, Matthew Maurer
Publikováno v:
Clinical Breast Cancer. 20:80-86
Background Epidermal growth factor receptor (EGFR) is frequently overexpressed in metastatic triple-negative breast cancer (mTNBC). One strategy for overcoming resistance to EGFR inhibition is concomitant inhibition of downstream signaling. The antid
Autor:
Patrizia Mondello, Alexandra Smith, Brian Link, Andrew Feldman, Thomas Habermann, Yucai Wang, Ivana Micallef, Patrick Johnston, Grzegorz Nowakowski, James Cerhan, Matthew Maurer, Stephen Ansell
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S389
Autor:
Patrizia Mondello, Alexandra Smith, Brian Link, Andrew Feldman, Thomas Habermann, Yucai Wang, Ivana Micallef, Patrick Johnston, Grzegorz Nowakowski, James Cerhan, Matthew Maurer, Stephen Ansell
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S173
Autor:
Madeleine B Hopson, Kevin Kalinsky, Katherine D. Crew, Matthew Maurer, Dawn L. Hershman, Shing Lee, Melissa K. Accordino, Meghna S. Trivedi
Publikováno v:
Breast Cancer Research and Treatment.
Propranolol regulates angiogenesis in pre-clinical models and reduces distant breast cancer (BC) metastases in observational studies. We assessed the feasibility of combining propranolol with neoadjuvant chemotherapy (NAC) in patients with BC. Women
Autor:
Katherine D. Crew, DL Hershman, Sohyae Lee, Kevin Kalinsky, Matthew Maurer, Trivedi, Melissa K. Accordino, Kathleen Fenn
Publikováno v:
Cancer Research. 79:P6-18
Background: The epidermal growth factor receptor (EGFR) is frequently overexpressed in triple negative breast cancer (TNBC). However, EGFR inhibitors have not shown efficacy as monotherapy in TNBC. One strategy for overcoming resistance to EGFR inhib
Autor:
Tizita Z. Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J. Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S. Trivedi, Melissa Accordino, Katherine D. Crew, Dawn L. Hershman, Matthew Maurer, Simon Jones, Anthony High, Junmin Peng, Andrea Califano, Kevin Kalinsky, Jiyang Yu, Jose Silva
Publikováno v:
Nature cancer.
Inhibiting individual histone deacetylase (HDAC) is emerging as well-tolerated anticancer strategy compared with pan-HDAC inhibitors. Through preclinical studies, we demonstrated that the sensitivity to the leading HDAC6 inhibitor (HDAC6i) ricolinsta
Autor:
Tizita Z. Zeleke, Matthew Maurer, Meghna S. Trivedi, Ruby Wu, Katherine D. Crew, Mariano J. Alvarez, Pei Ling Chia, Sean A. Kelly, Qingfei Pan, Dawn L. Hershman, Min Yang, Andrea Califano, Jiyang Yu, Partha Mukhopadhyay, Melissa Kate Accordino, Maika Onishi, Cody Chiuzan, Erin Honan, Kathleen Fenn, Jose Silva, Simon Jones, Kevin Kalinsky
Publikováno v:
Cancer Research. 81:645-645
Despite the anticancer activity of pan-histone deacetylase (HDAC) inhibitors, their clinical use has been limited due to toxicity. However, the development of more specific inhibitors that selectively inhibit individual HDACs is emerging as a novel a